Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib with concurrent radiotherapy versus radiotherapy alone for stage II-III esophageal squamous cell carcinoma
ChiCTR-OIC-17011813Phase 2Recruiting
- Sponsor
- Nanchong City Central Hospital
- Start
- Jul 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Rivoceranib in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Nanchong City Central Hospital. Primary endpoints: Objective response rate and Progression-free survival. Started Jul 2017; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR-OIC-17011813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-17011813.